Systemic sclerosis
6 Mathai SC, Bueso M, Hummers LK, et al . Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Respir J 2010;35:95–104. 7 Affandi AJ, Radstake TRDJ, Marut W. Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment. Semin Immunopathol 2015;37:475–87. 8 Hickey PM, Lawrie A, Condliffe R. Circulating protein biomarkers in systemic sclerosis related pulmonary arterial hypertension: a review of published data. Front Med 2018;5:175. 9 Odler B, Foris V, Gungl A, et al . Biomarkers for pulmonary vascular remodeling in systemic sclerosis: a pathophysiological approach. Front Physiol 2018;9:587. 10 Rice LM, Mantero JC, Stratton EA, et al . Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2018;20:185. 11 Bauer Y, de Bernard S, Hickey P, et al . Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the detect cohort. Eur Respir J 2021;57:2002591. 12 Sanges S, Launay D, Rhee RL, et al . A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment- naïve systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2016;75:1457–65. 13 Chemla D, Castelain V, Hervé P, et al . Haemodynamic evaluation of pulmonary hypertension. Eur Respir J 2002;20:1314–31. 14 van den Hoogen F, Khanna D, Fransen J, et al . 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47. 15 LeRoy EC, Black C, Fleischmajer R, et al . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5. 16 Goh NSL, Desai SR, Veeraraghavan S, et al . Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008;177:1248–54. 17 Gold L, Ayers D, Bertino J, et al . Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010;5:e15004. 18 Rohloff JC, Gelinas AD, Jarvis TC, et al . Nucleic acid ligands with protein-like side chains: modified aptamers and their use as diagnostic and therapeutic agents. Mol Ther Nucleic Acids 2014;3:e201. 19 Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:1–25. 20 Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B 1995;57:289–300. 21 Valenzi E, Bulik M, Tabib T, et al . Single-Cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease. Ann Rheum Dis 2019;78:1379–87. 22 Tu L, Desroches-Castan A, Mallet C, et al . Selective BMP-9 inhibition partially protects against experimental pulmonary hypertension. Circ Res 2019;124:846–55. 23 Tu L, De Man FS, Girerd B, et al . A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. Am J Respir Crit Care Med 2012;186:666–76. 24 Huertas A, Tu L, Thuillet R, et al . Leptin signalling system as a target for pulmonary arterial hypertension therapy. Eur Respir J 2015;45:1066–80. 25 Bouvard C, Tu L, Rossi M, et al . Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. Cardiovasc Res 2022;118:1805–20. 26 Hanthazi A, Jespers P, Vegh G, et al . Chemerin added to endothelin-1 promotes rat pulmonary artery smooth muscle cell proliferation and migration. Front Physiol 2020;11:926. 27 Akamata K, Asano Y, Taniguchi T, et al . Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis. Rheumatology 2015;54:1308–16.
28 Chighizola CB, Raschi E, Privitera D, et al . Serum chemerin in systemic sclerosis: a novel marker of early diffuse disease? Clin Exp Rheumatol 2017;35 Suppl 106:223–4. 29 Sawicka K, Michalska-Jakubus M, Potembska E, et al . Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis. Postepy Dermatol Alergol 2019;36:551–65. 30 Ferland DJ, Watts SW. Chemerin: a comprehensive review elucidating the need for cardiovascular research. Pharmacol Res 2015;99:351–61. 31 Peng L, Chen Y, Li Y, et al . Chemerin Regulates the Proliferation and Migration of Pulmonary Arterial Smooth Muscle Cells via the ERK1/2 Signaling Pathway. Front Pharmacol 2022;13:767705. 32 Ferland DJ, Mullick AE, Watts SW. Chemerin as a driver of hypertension: a consideration. Am J Hypertens 2020;33:975–86. 33 Kaur J, Adya R, Tan BK, et al . Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun 2010;391:1762–8. 34 Bozaoglu K, Curran JE, Stocker CJ, et al . Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab 2010;95:2476–85. 35 Neves KB, Lobato NS, Lopes RAM, et al . Chemerin reduces vascular nitric oxide/ cGMP signalling in rat aorta: a link to vascular dysfunction in obesity? Clin Sci 2014;127:111–22. 36 Yamawaki H, Kameshima S, Usui T, et al . A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells. Biochem Biophys Res Commun 2012;423:152–7. 37 Kunimoto H, Kazama K, Takai M, et al . Chemerin promotes the proliferation and migration of vascular smooth muscle and increases mouse blood pressure. Am J Physiol Heart Circ Physiol 2015;309:H1017–28. 38 Kennedy AJ, Yang P, Read C, et al . Chemerin elicits potent constrictor actions via chemokine-like receptor 1 (CMKLR1), not G-protein-coupled receptor 1 (gpr1), in human and rat vasculature. J Am Heart Assoc 2016;5:e004421. 39 Ferland DJ, Darios ES, Neubig RR, et al . Chemerin-induced arterial contraction is G i - and calcium-dependent. Vascul Pharmacol 2017;88:30–41. 40 Wen J, Wang J, Guo L, et al . Chemerin stimulates aortic smooth muscle cell proliferation and migration via activation of autophagy in VSMCs of metabolic hypertension rats. Am J Transl Res 2019;11:1327–42. 41 Zabel BA, Silverio AM, Butcher EC. Chemokine-Like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol 2005;174:244–51. 42 Parolini S, Santoro A, Marcenaro E, et al . The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 2007;109:3625–32. 43 Wittamer V, Franssen J-D, Vulcano M, et al . Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003;198:977–85. 44 Saygin D, Tabib T, Bittar HET, et al . Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension. Pulm Circ 2020;10:1–15. 45 Omori A, Goshima M, Kakuda C, et al . Chemerin-9-induced contraction was enhanced through the upregulation of smooth muscle chemokine-like receptor 1 in isolated pulmonary artery of pulmonary arterial hypertensive rats. Pflugers Arch 2020;472:335–42. 46 Hanthazi A, Jespers P, Vegh G, et al . Chemerin influences endothelin- and serotonin-induced pulmonary artery vasoconstriction in rats. Life Sci 2019;231:116580. 47 Nakamura N, Naruse K, Kobayashi Y, et al . Chemerin promotes angiogenesis in vivo. Physiol Rep 2018;6:e13962. 48 Xiong W, Luo Y, Wu L, et al . Chemerin stimulates vascular smooth muscle cell proliferation and carotid neointimal hyperplasia by activating mitogen-activated protein kinase signaling. PLoS One 2016;11:e0165305.
Sanges S, et al . Ann Rheum Dis 2023; 82 :365–373. doi:10.1136/ard-2022-223237
373
Powered by FlippingBook